Skip to content
buyWeak cluster of 410b5-1 plan

Jones James bought $1,827 of CPIX

director at CUMBERLAND PHARMACEUTICALS INC. 1,426 shares at an average of $1.28, traded Oct 1, 2024, filed Nov 5, 2024.

Conviction score
15
Value
$1,827
1,426 shares
Holdings after
37,871
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001628280-24-045331, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2024POpen-market purchase
Common Stock10b5-1
+62$1.27$7936,507Nov 5, 2024
Oct 2, 2024POpen-market purchase
Common Stock10b5-1
+62$1.29$8036,569Nov 5, 2024
Oct 3, 2024POpen-market purchase
Common Stock10b5-1
+62$1.28$7936,631Nov 5, 2024
Oct 4, 2024POpen-market purchase
Common Stock10b5-1
+62$1.28$7936,693Nov 5, 2024
Oct 7, 2024POpen-market purchase
Common Stock10b5-1
+62$1.29$8036,755Nov 5, 2024
Oct 8, 2024POpen-market purchase
Common Stock10b5-1
+62$1.30$8136,817Nov 5, 2024
Oct 9, 2024POpen-market purchase
Common Stock10b5-1
+62$1.31$8136,879Nov 5, 2024
Oct 10, 2024POpen-market purchase
Common Stock10b5-1
+62$1.32$8236,941Nov 5, 2024
Oct 11, 2024POpen-market purchase
Common Stock10b5-1
+62$1.39$8637,003Nov 5, 2024
Oct 14, 2024POpen-market purchase
Common Stock10b5-1
+62$1.37$8537,065Nov 5, 2024
Oct 15, 2024POpen-market purchase
Common Stock10b5-1
+62$1.30$8137,127Nov 5, 2024
Oct 16, 2024POpen-market purchase
Common Stock10b5-1
+62$1.25$7837,189Nov 5, 2024
Oct 17, 2024POpen-market purchase
Common Stock10b5-1
+62$1.30$8137,251Nov 5, 2024
Oct 18, 2024POpen-market purchase
Common Stock10b5-1
+62$1.28$7937,313Nov 5, 2024
Oct 21, 2024POpen-market purchase
Common Stock10b5-1
+62$1.25$7837,375Nov 5, 2024
Oct 22, 2024POpen-market purchase
Common Stock10b5-1
+62$1.25$7837,437Nov 5, 2024
Oct 23, 2024POpen-market purchase
Common Stock10b5-1
+62$1.26$7837,499Nov 5, 2024
Oct 24, 2024POpen-market purchase
Common Stock10b5-1
+62$1.24$7737,561Nov 5, 2024
Oct 25, 2024POpen-market purchase
Common Stock10b5-1
+62$1.23$7637,623Nov 5, 2024
Oct 28, 2024POpen-market purchase
Common Stock10b5-1
+62$1.25$7837,685Nov 5, 2024
Oct 29, 2024POpen-market purchase
Common Stock10b5-1
+62$1.24$7737,747Nov 5, 2024
Oct 30, 2024POpen-market purchase
Common Stock10b5-1
+62$1.32$8237,809Nov 5, 2024
Oct 31, 2024POpen-market purchase
Common Stock10b5-1
+62$1.20$7437,871Nov 5, 2024

Related signals

Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Krogulski Kenneth
director
$8,2094,716
25Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
KAZIMI A J
Chairman and CEO
$1,318769
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Jones James
director
$1,318769
15Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Young Caroline
director
$256154
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Krogulski Kenneth
director
$9,3488,029
25Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
KAZIMI A J
Chairman and CEO
$1,7551,506
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Jones James
director
$1,7551,506
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Young Caroline
director
$755647
15Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
Krogulski Kenneth
director
$9,1067,107
20Weakbuy 410b5-1CPIX
CUMBERLAND PHARMACEUTICALS INC
KAZIMI A J
Chairman and CEO
$1,8271,426

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.